Univest
Univest
  • Markets

Accretion Nutraveda (ANL) Share Price Falls 12.11% in Latest Session

  • November 20, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Accretion Nutraveda Share Price
Accretion Nutraveda (ANL) share price fell to Rs 296.2 today, down 12.11% from the previous close. Market cap was Rs 243.99 crore.

Accretion Nutraveda Share Price fell sharply to Rs 296.20, down 12.11% from the previous close of Rs 337, while market capitalisation stood at Rs 243.99 crore. The move keeps Accretion Nutraveda Share Price in focus for readers tracking stock market today action in the Healthcare sector, especially because the decline came without a company-specific catalyst that can be established from the available figures. Univest data confirms the move itself, though no company-specific trigger has been identified. The latest Univest figures also place the company in the Micro Cap category, which matters for context because price moves in this segment can appear larger in percentage terms even when the absolute rupee move is measured against a modest market value.

For anyone following Accretion Nutraveda Share Price Today, the stock opened at Rs 296.20, touched a high of Rs 296.20 and a low of Rs 296.20, which shows that the entire move was captured at one printed level in the current session so far. The focus now shifts from the headline decline to what the valuation and profitability metrics say about the business. Univest tracks these numbers together so investors can read the price move alongside fundamentals rather than in isolation.

Table of Contents

Toggle
  • Accretion Nutraveda (ANL) Share Price Today: Price Action Analysis
  • Accretion Nutraveda (ANL) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Accretion Nutraveda
  • About Accretion Nutraveda
  • Track Accretion Nutraveda Share Price on Univest
  • Frequently Asked Questions
    • Why did Accretion Nutraveda Share Price fall today?
    • What is Accretion Nutraveda Share Price today?
    • What is Accretion Nutraveda market capitalisation?
    • How does Accretion Nutraveda Share Price compare with the healthcare benchmark?
    • Is Accretion Nutraveda Share Price expensive versus peers?
    • What do EPS and book value mean for Accretion Nutraveda Share Price?
    • Does Accretion Nutraveda pay a dividend?
    • What are the key return ratios for Accretion Nutraveda?
    • What should investors watch next in Accretion Nutraveda Share Price?

Accretion Nutraveda (ANL) Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 296.2
Previous Close Rs 337
Today's Move -Rs 40.80 (-12.11%)
Open Rs 296.2
High Rs 296.2
Low Rs 296.2
Market Capitalisation Rs 243.99 crore
Market Cap Category Micro Cap

Accretion Nutraveda Share Price Today shows a clear one-session decline of Rs 40.80 from the previous close of Rs 337, or 12.11%. The current price is Rs 296.20, and the day open, day high and day low are all Rs 296.20, which means the stock has traded at the same level recorded in this update. For readers scanning Accretion Nutraveda Share Price Live, this is a straightforward price fall rather than a broad range-bound move. The company’s market capitalisation of Rs 243.99 crore places it in the Micro Cap category, and that size context matters when reading Accretion Nutraveda Share Price because smaller companies often show sharp percentage swings on price movement. Accretion Nutraveda Share Price Today therefore reflects a marked re-pricing in the latest session, and the next analytical step is to check whether the underlying fundamentals justify the current level.

Accretion Nutraveda (ANL) Fundamental Analysis

Metric Value
Market Capitalisation Rs 243.99 crore
P/E Ratio 48.14x
P/B Ratio 7.73x
ROE 27.68%
ROCE 30.19%
EPS Rs 7
Book Value Per Share Rs 43.6
Dividend Yield 0%

Accretion Nutraveda (ANL) fundamental metrics show P/E 48.14x, P/B 7.73x, ROE 27.68%, ROCE 30.19%. Read together, these ratios describe the company’s position rather than a recommendation.

Accretion Nutraveda has a market capitalisation of Rs 243.99 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 48.14x, P/B at 7.73x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 27.68% and ROCE of 30.19%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 7, book value per share of Rs 43.6, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.79x, median ROE of 11.23%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric Value
Sector Healthcare
Industry Pharmaceuticals & Drugs
Benchmark Scope same industry
Company P/E Ratio 48.14x
Benchmark Median P/E 30.79x
Benchmark Average P/E 59.37x
Benchmark P/E Range 2.73x to 1,399.41x
Company P/B Ratio 7.73x
Benchmark Median P/B 2.85x
Benchmark Average P/B 3.42x
Company ROE 27.68%
Benchmark Median ROE 11.23%
Benchmark Average ROE 4.65%
Company ROCE 30.19%
Benchmark Median ROCE 13.1%
Benchmark Average ROCE 12.03%
Company Market Capitalisation Rs 243.99 crore
Benchmark Median Market Cap Rs 790.89 crore
Benchmark Average Market Cap Rs 14,695.63 crore

Accretion Nutraveda (ANL) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Accretion Nutraveda (ANL) has a P/E ratio of 48.14x, which is above the benchmark median of 30.79x, a difference of +56.35%. The P/E comparison frames valuation; it is not a signal to buy or sell.

Accretion Nutraveda (ANL) has a ROE of 27.68%, which is above the benchmark median of 11.23%, a difference of +146.48%. Accretion Nutraveda (ANL) has a ROCE of 30.19%, which is above the benchmark median of 13.1%, a difference of +130.46%.

Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Sun Pharmaceutical Industries SUNPHARMA 4,49,227.49 41.64 5.11 14.85 19.11
Divi's Laboratories DIVISLAB 2,93,873.72 88.24 16.49 16.19 21.51
Torrent Pharmaceuticals TORNTPHARM 1,76,412.71 82.66 9.56 26.76 19.27
Laurus Labs LAURUSLABS 1,25,460.5 92.83 20.52 18.31 18.2
Zydus Lifesciences ZYDUSLIFE 1,19,201.71 28.64 4.3 19.69 21.39

Accretion Nutraveda (ANL) has a P/E ratio of 48.14x compared with the displayed peer median of 82.66x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 27.68% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 30.19% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Accretion Nutraveda (ANL) has a market capitalisation of Rs 243.99 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Accretion Nutraveda

  • Accretion Nutraveda Share Price fell 12.11% to Rs 296.20, making the latest session the main market event.
  • The stock remains in the Micro Cap category with market capitalisation of Rs 243.99 crore.
  • P/E of 48.14 and P/B of 7.73 keep valuation central to Accretion Nutraveda Share Price analysis.
  • ROE of 27.68% and ROCE of 30.19% are higher than the industry medians in the healthcare benchmark.
  • EPS of Rs 7, book value of Rs 43.6 and dividend yield of 0.00% give investors a compact fundamental snapshot.

About Accretion Nutraveda

Accretion Nutraveda operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The available figures point to a listed company with a Micro Cap market profile and a business tracked by valuation, return and earnings metrics. Accretion Nutraveda Share Price is therefore best understood in the context of a healthcare name where investors are comparing current price, earnings power, book value and capital returns. The stock’s exact business mix, product split and segment revenue contribution are not provided here, so the clearest verified view is that it belongs to the pharmaceuticals and drugs space and is analysed alongside the wider healthcare benchmark.

Track Accretion Nutraveda Share Price on Univest

Use Accretion Nutraveda (ANL) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.

You can follow Accretion Nutraveda Share Price on Univest for live share price updates, key fundamental ratios, 52-week levels and broader market insights in one place. Univest also keeps the latest company context, peer comparison and sector view together, which helps readers review Accretion Nutraveda Share Price without searching across multiple screens.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why did Accretion Nutraveda Share Price fall today?

Ans. Accretion Nutraveda Share Price fell 12.11% to Rs 296.20 from Rs 337. According to Univest data, the price event is confirmed, but no company-specific catalyst is established from the available figures.

What is Accretion Nutraveda Share Price today?

Ans. Accretion Nutraveda Share Price today is Rs 296.20. The move is down Rs 40.80, and the stock’s day open, high and low are all at the same level in the current update.

What is Accretion Nutraveda market capitalisation?

Ans. Accretion Nutraveda has a market capitalisation of Rs 243.99 crore. That places it in the Micro Cap category and helps frame the stock’s price move within a smaller company-size context.

How does Accretion Nutraveda Share Price compare with the healthcare benchmark?

Ans. Accretion Nutraveda Share Price trades at a P/E of 48.14 versus the industry median of 30.79 and a P/B of 7.73 versus 2.85. Its ROE and ROCE are also above benchmark medians.

Is Accretion Nutraveda Share Price expensive versus peers?

Ans. Accretion Nutraveda Share Price sits above Zydus Lifesciences and Sun Pharma on P/E, but below Divi's Laboratories, Torrent Pharmaceuticals and Laurus Labs. The stock also has a much smaller market cap than every listed peer shown.

What do EPS and book value mean for Accretion Nutraveda Share Price?

Ans. EPS is Rs 7 and book value is Rs 43.6. EPS shows earnings attributable to each share, while book value per share shows the accounting net worth behind each share in the latest figures.

Does Accretion Nutraveda pay a dividend?

Ans. The dividend yield is 0.00%, so no current dividend yield is reflected in the latest Univest figures. Accretion Nutraveda Share Price should therefore be read more through valuation and return metrics than income yield.

What are the key return ratios for Accretion Nutraveda?

Ans. Accretion Nutraveda reports ROE of 27.68% and ROCE of 30.19%. Those figures are both above the benchmark medians for the same industry, which gives important context for Accretion Nutraveda Share Price analysis.

What should investors watch next in Accretion Nutraveda Share Price?

Ans. Investors should watch whether Accretion Nutraveda Share Price holds near Rs 296.20 and whether the market continues to weigh its high P/E and P/B against strong ROE and ROCE. Univest will keep the update central.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply